• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    VolitionRX Limited filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/20/25 4:06:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    vnrx_8k.htm
    0000093314false--12-3100000933142025-06-182025-06-18iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

     Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported):  June 18, 2025

     

    VolitionRx Limited

     (Exact name of registrant as specified in its charter)

     

    Delaware

     

    001-36833

     

    91-1949078

    (State or other jurisdiction

     

    (Commission File Number)

     

    (IRS Employer

    of Incorporation)

     

     

     

    Identification Number)

     

    1489 West Warm Springs Road, Suite 110

    Henderson, Nevada 89014

    (Address of principal executive offices and Zip Code)

     

    +1 (646) 650-1351

    (Registrant’s telephone number, including area code )

     

    Not applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading Symbol(s)

     

    Name of Each Exchange on which Registered

    Common Stock, par value $0.001 per share

     

    VNRX

     

    NYSE American, LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    On June 18, 2025, VolitionRx Limited (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved a Certificate of Second Amendment (the “Amendment”) of the Second Amended and Restated Certificate of Incorporation (the “Restated Certificate”), providing for an increase in authorized shares from one hundred seventy-five million (175,000,000) shares to three hundred twenty-five million (325,000,000) shares, consisting of three hundred twenty-five million (325,000,000) shares of common stock, par value $0.001 per share. The Amendment had previously been approved by the Board of Directors on April 2, 2025, subject to the approval of the Company’s Stockholders. The Amendment became effective upon its filing with the Secretary of State of the State of Delaware on June 18, 2025.

     

    The Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to such Exhibit 3.1.

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    At the Annual Meeting held at 3:30 p.m. British Summer Time on June 18, 2025 at 93-95 Gloucester Place, London, W1U 6JQ, United Kingdom, the Company’s stockholders voted on four proposals. The Company had 100,775,334 shares of common stock outstanding on April 25, 2025, the record date for the Annual Meeting, of which 51,635,355 shares of common stock were present in person or represented by proxy at the Annual Meeting.

     

    The following sets forth the final voting results of the four proposals voted upon by the Company’s stockholders at the Annual Meeting. These matters are described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025 (the “Proxy Statement”).

     

    Proposal 1: The stockholders elected eight members to the Board of Directors to hold office until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. The voting results are as follows:

     

    Nominee

     

    Votes For

     

     

    Votes Withheld

     

     

    Broker Non-Votes

     

    Dr. Phillip Barnes

     

     

    35,018,471

     

     

     

    1,964,275

     

     

     

    14,652,609

     

    Dr. Alan Colman

     

     

    35,024,256

     

     

     

    1,958,490

     

     

     

    14,652,609

     

    Mickie Henshall

     

     

    35,363,392

     

     

     

    1,619,354

     

     

     

    14,652,609

     

    Guy Innes

     

     

    34,317,785

     

     

     

    2,664,961

     

     

     

    14,652,609

     

    Kim Nguyen

     

     

    34,646,196

     

     

     

    2,336,550

     

     

     

    14,652,609

     

    Cameron Reynolds

     

     

    36,104,993

     

     

     

    877,753

     

     

     

    14,652,609

     

    Dr. Ethel Rubin

     

     

    36,125,178

     

     

     

    857,568

     

     

     

    14,652,609

     

    Timothy Still

     

     

    36,004,285

     

     

     

    978,461

     

     

     

    14,652,609

     

     

    Proposal 2: The stockholders ratified the selection of Sadler, Gibb & Associates, LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The voting results are as follows:

     

    Votes For

     

    Votes Against

     

    Votes Abstained

     

    51,261,805

     

    330,721

     

    42,829

     

     

    Proposal 3: The stockholders approved, by a non-binding advisory vote, the compensation of the Company’s named executive officers as described in the Proxy Statement. The voting results are as follows:

     

    Votes For

     

    Votes Against

     

    Votes Abstained

     

    Broker Non-Votes

    34,417,170

     

    2,340,233

     

    225,343

     

    14,652,609

     

    Proposal 4: The stockholders approved the Amendment of the Restated Certificate. The voting results are as follows:

     

    Votes For

     

    Votes Against

     

    Votes Abstained

     

    49,458,528

     

    1,791,694

     

    385,133

     

     

    No other matters were presented for consideration or stockholder action at the Annual Meeting.

     

     
    2

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit

     

     

    Number

     

    Description

     

     

     

    3.1

     

    Certificate of Second Amendment of the Second Amended and Restated Certificate of Incorporation.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document).

     

     
    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    VOLITIONRX LIMITED

     

     

    Date: June 20, 2025

    By:  

    /s/ Cameron Reynolds

     

     

     

    Cameron Reynolds

     

     

     

    Chief Executive Officer & President

     

     

     
    4

     

     

    EXHBIIT INDEX

     

    Exhibit

     

     

    Number

     

    Description

     

     

     

    3.1

     

    Certificate of Second Amendment of the Second Amended and Restated Certificate of Incorporation.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document).

     

     
    5

     

     

    Get the next $VNRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled for Friday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the second quarter ended June 30, 2025. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.   Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground

    8/14/25 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, August 15, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34

    8/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

    HENDERSON, Nev., Aug. 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of (i)  156,250 shares of its common stock to certain directors and executive officers of the Company (collectively, the "Insiders") at an offering price of $0.64 per share, and (ii) 1,734,375 shares of its common stock, together with common stock purchase warrants to purchase up to 1,734,375 shares of common stock (individually, a "Warrant" and collectively, the "Warrants"), to certain other existing stockholders of the Company at a combined offering

    8/4/25 4:01:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Innes Guy Archibald bought $50,000 worth of shares (78,125 units at $0.64), increasing direct ownership by 9% to 966,814 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/6/25 9:00:21 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $50,000 worth of shares (78,125 units at $0.64), increasing direct ownership by 3% to 2,609,847 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/6/25 9:00:10 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    President and CEO Reynolds Cameron John bought $7,372 worth of shares (12,500 units at $0.59), increasing direct ownership by 0.54% to 2,331,722 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    6/16/25 8:27:54 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on VolitionRx with a new price target

    H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

    4/8/25 8:02:28 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx downgraded by The Benchmark Company

    The Benchmark Company downgraded VolitionRx from Buy to Hold

    2/1/23 7:40:33 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

    Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

    2/17/22 9:10:02 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Hughes Terig was granted 26,143 shares, increasing direct ownership by 5% to 533,770 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/19/25 4:06:32 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Group Chief Marketing Officer Batchelor Ann-Louise was granted 27,400 shares, increasing direct ownership by 21% to 159,886 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/19/25 4:06:24 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Secretary Rootsaert Rodney Gerard was granted 15,223 shares, increasing direct ownership by 11% to 149,233 units (SEC Form 4)

    4 - VOLITIONRX LTD (0000093314) (Issuer)

    8/19/25 4:06:17 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    SEC Filings

    View All

    Amendment: SEC Form 10-Q/A filed by VolitionRX Limited

    10-Q/A - VOLITIONRX LTD (0000093314) (Filer)

    8/15/25 5:16:42 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-Q filed by VolitionRX Limited

    10-Q - VOLITIONRX LTD (0000093314) (Filer)

    8/14/25 4:54:18 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - VOLITIONRX LTD (0000093314) (Filer)

    8/14/25 4:45:27 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Leadership Updates

    Live Leadership Updates

    View All

    Volition Issues Business Review 2024

    HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

    1/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Timothy I. Still as Chairman

    HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

    11/6/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Volition Appoints Dr. Ethel Rubin as an Independent Director

    HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

    9/30/24 4:10:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Financials

    Live finance-specific insights

    View All

    VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, August 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev., Aug. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, August 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited Second Quarter 2025 Earnings and Business Update Conference Call Date:     Friday, August 15, 2025Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 34

    8/8/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

    Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

    5/15/25 5:37:00 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

    Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate:     Friday, May 16, 2025 Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr

    5/12/25 8:30:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 4:05:14 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by VolitionRX Limited

    SC 13G - VOLITIONRX LTD (0000093314) (Subject)

    11/14/24 3:40:04 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

    SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

    2/14/24 4:05:45 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care